NEW YORK, NY / ACCESSWIRE / September 17, 2021 / Vincent Wong’s law firms announce that class actions have been initiated on behalf of certain shareholders of the following companies. If you have suffered prejudice, you have until the lead plaintiff deadline to request that the court appoint you lead plaintiff. There will be no obligation or cost to you.
CorMedix Inc. (NASDAQ: CRMD)
If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/cormedix-inc-loss-submission-form?prid=19653&wire=1
Lead applicant’s deadline: September 20, 2021
Class period: October 16, 2019 – May 13, 2021
The allegations against CRMD include that: (i) deficiencies existed with respect to an investigational drug product, DefenCath, the manufacturing process and / or the facility responsible for manufacturing DefenCath; (ii) in light of the aforementioned shortcomings, the Food and Drug Administration was unlikely to approve the new drug application DefenCath for catheter-related blood infections in its current form; (iii) the defendants had downplayed the actual extent of the deficiencies in the manufacturing process of DefenCath and / or the facility responsible for the manufacture of DefenCath; and (iv) accordingly, the Company’s public statements were materially false and misleading at all material times.
Zymergen Inc. (NASDAQ: ZY)
If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/zymergen-inc-loss-submission-form?prid=19653&wire=1
Lead applicant’s deadline: October 4, 2021
This lawsuit is on behalf of investors who purchased ZY common stock in accordance with and / or traceable to documents released as part of the Company’s initial public offering in April 2021.
The allegations against ZY include that: (1) during the qualification process for the Company’s optical film product, Hyaline, key customers encountered technical issues, including product shrinkage and incompatibility with customer processes ; (2) although the qualification process was essential in gaining market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated the demand for its products; (4) due to the foregoing, the timing of delivery of the Company’s products was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, the Defendants’ positive statements regarding the business, operations and prospects of the Company were substantially misleading and / or lacked reasonable basis.
Goutte d’eau inc. (NYSE: WDH)
If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/waterdrop-inc-loss-submission-form?prid=19653&wire=1
Lead applicant’s deadline: November 15, 2021
This legal action is being brought on behalf of all persons or entities who purchased US Waterdrop Depository Shares as part of the Company’s initial public offering in May 2021.
The allegations against WDH include that: (a) Waterdrop had achieved a substantial part of its historic revenue growth through illicit means which violated Chinese rules and regulations governing the insurance industry; (b) Waterdrop had been ordered by the Chinese government to shut down its mutual aid platform due to its non-compliance with Chinese law; (c) Waterdrop was under investigation by regulatory authorities for continued violations of Chinese law; (d) due to (a) – (c) above, there was a material undisclosed risk and a substantial likelihood that Waterdrop would be the subject of serious adverse action by regulatory authorities as a result of the IPO; (e) Waterdrop’s operating losses more than quadrupled in the first quarter of 2021 due to the cessation of its self-help business and rapid growth in customer acquisition costs; and (f) due to (a) – (e) above, the statements in the registration statement regarding Waterdrop’s historical financial and operating metrics and alleged market opportunities did not accurately reflect the activities, operations, financial results and the actual trajectory of the Company. in the pre-IPO period, were materially false and misleading, and lacked a factual basis.
For more information, contact Vincent Wong, Esq. either by email [email protected] or by phone at 212.425.1140.
Vincent Wong, Esq. is an experienced lawyer who has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Lawyer advertising. Past results do not guarantee similar results.
Vincent Wong, Esq.
39 Broadway East
New York, New York 10002
Email: [email protected]
THE SOURCE: Vincent Wong’s law firms
See the source version on accesswire.com: